Phellinus linteus and VEGF Inhibition

Meshima Anti-Angiogenesis & VEGF Inhibition

2 VEGF inhibition pathways

Phellinus linteus inhibits tumor angiogenesis through two documented mechanisms: suppressing VEGF secretion upstream by blocking AKT kinase in cancer cells, and blocking VEGFR-2 phosphorylation directly in endothelial cells, preventing VEGF signal reception.

Sliva et al., British Journal of Cancer, 2008; Lee et al., 2010

Dose-dependent

VEGF secretion from MDA-MB-231 breast cancer cells decreased in a dose-response manner with Phellinus linteus extract (Sliva 2008)

Wnt/β-catenin

a third angiogenesis-relevant pathway disrupted by PL protein-bound polysaccharide in colon cancer xenografts (Song 2011)

Sanghuangporus

the modern taxonomic name for the Phellinus linteus lineage, used in 2023 lung cancer research confirming STAT3 suppression (Wang 2023)

Sliva et al., British Journal of Cancer, 2008; Lee et al., 2010

View as image ↗

A taxonomy note before the science: Phellinus linteus has been reclassified in recent mycology literature as Sanghuangporus sanghuang, its updated scientific name following advances in genetic analysis of the Phellinus species complex. The older name still dominates the research literature before 2020, and the newer name appears in recent studies such as the 2023 Wang et al. paper on lung cancer. Both names refer to the same mushroom that is commonly called meshima (Japanese) or sanghuang (Chinese). Literature searches should use both names to find the full evidence base.

With that context: VEGF stands for vascular endothelial growth factor, a protein that acts as a growth signal specifically for blood vessels. When VEGF binds to its receptor on endothelial cells (the cells that line blood vessel walls), it triggers those cells to proliferate and migrate, forming new capillaries. Tumors exploit this process to build a blood supply for themselves, and VEGF suppression is one of the most validated strategies in cancer pharmacology.

Phellinus linteus inhibits VEGF signaling through two distinct documented pathways, and a third mechanism affecting angiogenesis-relevant signaling has been documented in colon cancer models. This article explains what the laboratory data shows, what the assays being used actually measure, and where the evidence gaps are. For the broader meshima introduction, see the meshima mushroom guide.

VEGF and Tumor Angiogenesis: What This Mushroom Is Targeting

Tumors face a supply problem. Beyond approximately 2 millimeters in diameter, a solid tumor cannot receive sufficient oxygen and nutrients by passive diffusion. To grow further, it must recruit new blood vessels. This process is called angiogenesis, and the primary molecular signal that drives it is VEGF.

Cancer cells often overproduce VEGF as a survival strategy. When VEGF binds to VEGFR-2, the main receptor for VEGF on endothelial cells, it activates a cascade of intracellular signaling that causes those cells to divide, migrate toward the VEGF source, and arrange themselves into tube-like structures that become new capillaries. A tumor with its own blood supply can now receive nutrients, expel metabolic waste, and, critically, shed cancer cells into the bloodstream for metastasis.

Inhibiting VEGF signaling is a well-validated approach in oncology. Bevacizumab (Avastin), approved for multiple cancers, is a monoclonal antibody that binds and neutralizes free VEGF in circulation. A class of drugs called tyrosine kinase inhibitors (including sorafenib and sunitinib) block VEGFR-2 directly at the receptor level. Both approaches have shown clinical benefit.

Phellinus linteus works at both points. One mechanism reduces how much VEGF cancer cells produce. A second mechanism blocks the receptor that responds to VEGF. The molecular evidence for both is documented in peer-reviewed laboratory research.^[2][1]

For the broader context on how PL's polysaccharide and phenolic compounds relate to its anti-tumor activity, the Phellinus linteus bioactive compounds article covers the compound-level picture.

VEGFR-2 Phosphorylation Inhibition: The Receptor-Level Data

Lee et al.'s 2010 study provides the most mechanistically specific VEGF-pathway data for Phellinus linteus available in the literature.^[1]

The research used HUVECs (human umbilical vein endothelial cells) as the experimental system. HUVECs are the standard cell type for angiogenesis research because they are real endothelial cells that respond to VEGF in ways that parallel angiogenesis in living tissue. The researchers ran three complementary assays.

First, proliferation: did the cells stop dividing? They did. PL extract significantly reduced HUVEC proliferation.

Second, migration: did the cells stop moving toward a VEGF source? They did. Endothelial cell migration is the step that directs where new vessels will form; inhibiting it prevents vessel formation even if cells are still alive.

Third, tube formation: did the cells stop arranging themselves into capillary-like tube structures? They did. Tube formation assays measure the final step of angiogenesis in cell culture, when endothelial cells organize into the hollow tubes that become functional blood vessels.

Underneath all three effects, the researchers measured VEGFR-2 phosphorylation. Phosphorylation is a molecular on/off switch: a kinase enzyme adds a phosphate group to a protein to activate it. When VEGF binds to VEGFR-2, the receptor phosphorylates itself, which activates the downstream cascade. PL extract inhibited this phosphorylation, effectively preventing the receptor from transmitting the VEGF signal even when VEGF was present.

The study also confirmed anti-angiogenic activity in vivo using a Matrigel plug model, in which a gel plug seeded with cells is implanted under the skin of mice and later scored for how many new blood vessels have grown into it. New vessel formation was reduced in plugs from PL-treated animals compared with controls.

Key Study · Receptor-level

Lee et al. (2010) · Journal of Ethnopharmacology

Population

Human umbilical vein endothelial cells (HUVECs), plus an in vivo Matrigel plug model in mice

Intervention

Methanol extract of Phellinus linteus and its solvent fractions

Comparator

Untreated endothelial cells / vehicle-treated plugs

Finding

The extract significantly inhibited HUVEC proliferation, migration, and tube formation, and suppressed VEGFR-2 phosphorylation, blocking the receptor that reads the VEGF signal. New vessel formation was also reduced in the in vivo Matrigel plug model.

preliminary Cell-culture and mouse-implant evidence; no human data.

Lee et al., Journal of Ethnopharmacology, 2010 (ref 1)

AKT Kinase and Upstream VEGF Suppression: The Sliva 2008 Data

While Lee's study addressed the receptor end of the VEGF pathway, Sliva et al.'s 2008 study in the British Journal of Cancer addressed the production end.^[2]

AKT is a protein kinase, an enzyme that activates other proteins by adding phosphate groups to them. It is part of a central cell survival pathway, often overactive in cancer cells, that promotes both cell growth and production of VEGF. When AKT is active, it drives cancer cells to secrete more VEGF. Blocking AKT reduces VEGF production at its source.

Sliva's team applied Phellinus linteus extract to MDA-MB-231 breast cancer cells, an aggressive human breast cancer cell line used extensively in cancer research because it models hard-to-treat triple-negative breast cancer. The results were specific: VEGF secretion from the cancer cells decreased in a clear dose-response relationship as PL concentration increased. More PL, less VEGF production.

The molecular basis: AKT phosphorylation at two specific sites (threonine 308 and serine 473, both of which must be phosphorylated for full AKT activation) was inhibited by PL extract. Blocking both sites shuts down AKT more completely than blocking either site alone. With AKT suppressed, the cells produced less VEGF.

The study also measured capillary morphogenesis of human aortic endothelial cells exposed to conditioned medium from PL-treated cancer cells, meaning fluid that the cancer cells had secreted. Aortic endothelial cells exposed to the PL-treated cancer cell secretions formed fewer capillary-like structures than those exposed to untreated cancer cell secretions, consistent with less VEGF in the conditioned medium.

This upstream mechanism (less VEGF produced) is conceptually distinct from and complementary to the downstream mechanism (VEGFR-2 blocked). A tumor encountering Phellinus linteus would face both reduced VEGF supply and reduced receptor capacity for whatever VEGF remained.

Key Study · Production-level

Sliva et al. (2008) · British Journal of Cancer

Population

MDA-MB-231 human triple-negative breast cancer cells

Intervention

Phellinus linteus extract (0–1.0 mg/mL)

Comparator

Untreated cancer cells

Finding

VEGF secretion from the cancer cells fell in a dose-response manner. The mechanism traced to inhibition of AKT kinase phosphorylation at both Thr308 and Ser473; endothelial cells exposed to conditioned medium from PL-treated cancer cells formed fewer capillary-like structures.

preliminary In vitro breast cancer model; no human VEGF data.

Sliva et al., British Journal of Cancer, 2008 (ref 2)

Sliva's 2010 comprehensive review in Experimental and Therapeutic Medicine synthesized the broader PL anti-cancer evidence across breast, prostate, lung, and colon cancer models, identifying AKT inhibition and VEGF suppression as central mechanisms across multiple cancer types.^[3]

Beyond Breast Cancer: Colon Models and a Third Pathway

Song et al.'s 2011 study in BMC Cancer extended the anti-angiogenic evidence into a different cancer type and introduced a third mechanistic pathway.^[4]

The study tested a protein-bound polysaccharide fraction from Phellinus linteus in SW480 human colon cancer cells and in mouse xenograft models (tumors grown in immunodeficient mice from human cancer cells). The results: tumor growth was inhibited, invasion was reduced, and microvessel density inside the tumors was lower in PL-treated mice than in controls. Microvessel density is a direct histological measure of angiogenesis: more blood vessels per unit of tumor tissue means more successful angiogenesis.

The signaling pathway involved in the colon cancer model was Wnt/β-catenin. This is a separate signaling cascade from AKT and VEGFR-2, one that governs cell proliferation, differentiation, and migration and is overactive in many colorectal cancers. PL polysaccharide altered β-catenin levels in the cancer cells, reducing the pathway's activity.

Wang et al.'s 2023 study, using the updated taxonomic designation Sanghuangporus sanghuang, confirmed anti-tumor activity against lung cancer cells (A549 and H1650 lines) with dose-dependent inhibition of migration and invasion at 6 to 9 mg/mL.^[5] The downstream mechanism in the lung cancer data included suppression of STAT3 (a protein that promotes cancer cell survival and drives genes for proliferation), Bcl-2 (an anti-apoptosis protein), CDK4, and Cyclin D1. Tumor growth inhibition was confirmed in a mouse model.

The consistent anti-angiogenic signal across breast, colon, and lung cancer models, operating through multiple distinct pathways, suggests that PL's anti-angiogenic activity is not specific to one cancer type or one mechanistic route. Qin et al.'s 2023 systematic review characterized the beta-(1,3)-linked glucan polysaccharides as the primary bioactive fraction responsible, providing the structural context for which compounds drive these effects.^[6]

For how this anti-angiogenic evidence compares to pharmaceutical VEGF inhibitors, the meshima vs. pharmaceutical angiogenesis inhibitors article addresses that comparison directly, including the evidence scale gap. For the parallel anti-cancer evidence base for reishi, which also suppresses VEGF through some overlapping mechanisms, the ganoderic acids and cancer research article provides a useful cross-mushroom comparison.

What the Evidence Gaps Mean for Interpreting This Research

The VEGF inhibition data for Phellinus linteus is mechanistically specific and uses validated assay systems. HUVEC tube formation, VEGFR-2 phosphorylation measurement, AKT kinase activity, and tumor microvessel density are all standard endpoints in angiogenesis research. The findings are not vague "immune boosting" claims.

The gap is at the clinical level. All direct VEGF suppression data comes from cancer cell lines in culture or from mouse xenograft models. No published clinical trial has measured VEGF levels, microvessel density, or angiogenesis-related biomarkers in human patients receiving Phellinus linteus. The only human randomized controlled trial currently published for Phellinus linteus (Ku et al. 2022, a CONSORT-compliant, double-blind, placebo-controlled pilot trial in 30 participants) measured immune function markers, not tumor vascularity or any angiogenesis endpoint.^[7]

Moving from preclinical to clinical evidence requires studies measuring whether PL supplementation actually changes VEGF levels or tumor vascularity in human patients with cancer, and whether those changes correlate with clinical outcomes. That research has not been conducted.

The honest interpretation: the laboratory evidence identifies specific molecular targets and demonstrates activity at those targets in relevant cell and animal systems. The clinical question of whether this translates to meaningful anti-tumor effects in people with cancer has not been answered.

Evidence Review

1. Cell-culture studiescompleted

   HUVEC and cancer-cell assays document VEGFR-2 and AKT effects (Lee 2010, Sliva 2008).

2. Animal modelscompleted

   Colon and lung xenografts show reduced microvessel density and tumor growth (Song 2011, Wang 2023).

3. Human case reports on angiogenesismissing

   No published reports measuring vascular endpoints in PL-treated patients.

4. Small human trials (VEGF endpoints)missing

   The one human RCT (Ku 2022) measured immune markers, not tumor vascularity.

5. Large randomized trialsmissing

   None conducted for anti-angiogenic outcomes.

The anti-angiogenic evidence is consistent and mechanistically specific, but it stops at the animal-model stage. No human study has measured whether Phellinus linteus changes VEGF levels or tumor vascularity.

Lee 2010 (ref 1), Sliva 2008 (ref 2), Song 2011 (ref 4), Wang 2023 (ref 5), Ku 2022 (ref 7)

For the broader evidence landscape including mushrooms where clinical cancer adjuvant data exists, the Ganoderma lucidum as cancer adjunct article covers a species with a more developed human clinical evidence base. The how meshima starves tumors overview covers the angiogenesis biology more broadly.

Safety

Moderate

This is laboratory research, not a cancer treatment recommendation

Concern

The VEGF and angiogenesis findings described here come entirely from cell-culture and animal studies. No human trial has shown that Phellinus linteus shrinks tumors, suppresses angiogenesis in patients, or improves cancer outcomes. Treating a preclinical mechanism as if it were a proven therapy can lead people to delay or substitute evidence-based care.

What the research says

Phellinus linteus should not be used to treat, prevent, or replace conventional cancer therapy. Anyone considering it as a supplement alongside cancer treatment should discuss it first with their oncologist, because mushroom extracts can interact with chemotherapy, immunotherapy, and anticoagulants.

Particularly relevant for: People with cancer or a cancer history

What to do

Talk to your oncology team before adding any mushroom supplement; do not delay standard treatment.

Editorial safety note; no human efficacy data exists for Phellinus linteus in cancer (see Ku 2022, ref 7, which measured immunity, not tumor outcomes).

This article is educational and is not medical advice.

The Bottom Line

Phellinus linteus (now also classified as Sanghuangporus sanghuang) inhibits tumor angiogenesis through two documented pathways: blocking AKT kinase to suppress VEGF secretion from cancer cells (Sliva 2008) and directly inhibiting VEGFR-2 phosphorylation in endothelial cells (Lee 2010). A third pathway, Wnt/β-catenin, was identified in colon cancer xenografts with reduced microvessel density (Song 2011). The 2023 Wang data shows STAT3 suppression in lung cancer models. All VEGF-specific data is preclinical; no human clinical trial has measured VEGF or angiogenesis endpoints for Phellinus linteus.

Frequently Asked Questions

What is Phellinus linteus?

Phellinus linteus is a bracket fungus used in traditional East Asian medicine, commonly called meshima in Japan and sanghuang in China. It has been recently reclassified as Sanghuangporus sanghuang in updated taxonomy. In cancer research, it is one of the most studied medicinal mushrooms for anti-tumor mechanisms including angiogenesis inhibition, apoptosis induction, and immune activation. Its primary bioactive compounds are beta-(1,3)-linked glucan polysaccharides and phenolic compounds.

How does Phellinus linteus inhibit VEGF?

Through two documented pathways. First, Sliva et al. (2008) showed that PL blocks AKT kinase (a protein that drives VEGF production in cancer cells), reducing VEGF secretion from breast cancer cells in a dose-dependent manner. Second, Lee et al. (2010) showed that PL directly blocks VEGFR-2 phosphorylation in endothelial cells, preventing VEGF from activating its main receptor even when VEGF is present. Both mechanisms were demonstrated in standardized laboratory models.

What is VEGFR-2 and how does Phellinus linteus affect it?

VEGFR-2 (vascular endothelial growth factor receptor 2) is the primary cell surface receptor through which VEGF triggers blood vessel growth. When VEGF binds to VEGFR-2, the receptor activates itself through phosphorylation (adding a phosphate group), which triggers a cascade that causes endothelial cells to divide and form new blood vessels. Lee et al. (2010) found that Phellinus linteus extract inhibited this phosphorylation step, effectively blocking the receptor from transmitting the VEGF signal. This suppressed endothelial cell proliferation, migration, and tube formation in laboratory assays.

Is Phellinus linteus the same as meshima or sanghuang?

Yes. Phellinus linteus is the long-standing scientific name for the fungus called meshima in Japanese traditional medicine and sanghuang in Chinese traditional medicine. Recent taxonomic revision has reclassified it as Sanghuangporus sanghuang, and this newer name appears in research published after approximately 2020. The three names refer to the same organism. When searching the literature, using both Phellinus linteus and Sanghuangporus sanghuang will capture the full evidence base across older and newer publications.

What research exists on Phellinus linteus and cancer?

The most direct VEGF-pathway studies are Lee 2010 (VEGFR-2 inhibition, HUVEC assays) and Sliva 2008 (AKT→VEGF suppression in breast cancer cells). Song 2011 added colon cancer xenograft data showing reduced microvessel density and Wnt/β-catenin disruption. Wang 2023 (Sanghuangporus sanghuang) showed lung cancer growth inhibition via STAT3 suppression. Sliva's 2010 comprehensive review synthesized evidence across breast, prostate, lung, and colon models. The only human RCT (Ku 2022) tested immune effects, not anti-angiogenic endpoints. No clinical trial has measured VEGF or tumor vascularity in human patients.

Sources & References

1. 1RTHM-00349·Lee, Yeon Sil et al. (2010). “Anti-angiogenic activity of methanol extract of Phellinus linteus and its fractions..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00271·Sliva, D et al. (2008). “Phellinus linteus Extract in Breast-Cancer Cell Models: What This 2008 Study Actually Found.” British journal of cancer.Study breakdown →PubMed →↩
3. 3RTHM-00364·Sliva, Daniel (2010). “Medicinal mushroom Phellinus linteus as an alternative cancer therapy..” Experimental and therapeutic medicine.Study breakdown →PubMed →↩
4. 4RTHM-00437·Song, Kyoung-Sub et al. (2011). “Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cells..” BMC cancer.Study breakdown →PubMed →↩
5. 5RTHM-01817·Wang, Weike et al. (2023). “Sanghuangporus sanghuang extract inhibits the proliferation and invasion of lung cancer cells in vitro and in vivo..” Nutrition research and practice.Study breakdown →PubMed →↩
6. 6RTHM-01770·Qin, Dandan et al. (2023). “Polysaccharides from Phellinus linteus: A systematic review of their extractions, purifications, structures and functions..” International journal of biological macromolecules.Study breakdown →PubMed →↩
7. 7RTHM-01555·Ku, Yong Ho et al. (2022). “Efficacy of Phellinus linteus extract on immunity enhancement: A CONSORT-randomized, double-blind, placebo-controlled pilot trial..” Medicine.Study breakdown →PubMed →↩